Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B‐cell lymphoma, leg type

The primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT) has a poor prognosis. R‐CHOP with or without radiotherapy is the available recommendations for first‐line treatment. Relapses/refractory cases are frequent with no standardized therapeutic guidelines. Lenalidomide seems to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Dhafiri, Mahdi, Sicre de Fontbrune, Flore, Marinho, Eduardo, Deschamps, Lydia, Di‐Lucca, Julie, Crickx, Beatrice, Descamps, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509882/
https://www.ncbi.nlm.nih.gov/pubmed/31110725
http://dx.doi.org/10.1002/ccr3.2137
Descripción
Sumario:The primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT) has a poor prognosis. R‐CHOP with or without radiotherapy is the available recommendations for first‐line treatment. Relapses/refractory cases are frequent with no standardized therapeutic guidelines. Lenalidomide seems to be an excellent therapeutic option as a second‐line treatment of relapsed PCDLBCL‐LT.

Ejemplares similares